- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens teams up with NYU Medical Center
NYU Medical Center has entered into a strategic alliance with Siemens Medical Solutions. The cornerstone of the alliance is a seven-year agreement that makes Siemens the exclusive supplier of the center's radiology imaging. The commercial value of the
NYU Medical Center has entered into a strategic alliance with Siemens Medical Solutions. The cornerstone of the alliance is a seven-year agreement that makes Siemens the exclusive supplier of the center's radiology imaging. The commercial value of the agreement will exceed $110 million, according to the company. The agreement covers approximately 100 advanced imaging systems, including a high-resolution research 7T MR scanner. Also included will be CTs, PET scanners, mammography, digital x-ray, and ultrasound equipment, as well as PACS. Due to the size and scope of the agreement, NYU and Siemens expect it will take four years to install all of the equipment and systems.
Another key aspect of the alliance is the commitment from both partners to MR imaging research. NYU plans to construct a new MR research facility near its midtown campus in Manhattan to house some of the new equipment, including the new 7T system, which will require a special room reinforced by some 300 tons of steel. Siemens will also install two 3T scanners dedicated to imaging research, particularly of the human brain, liver, kidneys, and prostate.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
